- Home
- PTHL vs IKNA Comparison
PTHL vs IKNA Comparison
Compare PTHL & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTHL
- IKNA
- Stock Information
- Founded
- PTHL 1998
- IKNA 2016
- Country
- PTHL China
- IKNA United States
- Employees
- PTHL N/A
- IKNA N/A
- Industry
- PTHL
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- PTHL
- IKNA Health Care
- Exchange
- PTHL Nasdaq
- IKNA Nasdaq
- Market Cap
- PTHL 72.9M
- IKNA 82.5M
- IPO Year
- PTHL 2024
- IKNA 2021
- Fundamental
- Price
- PTHL $4.54
- IKNA $1.71
- Analyst Decision
- PTHL
- IKNA Buy
- Analyst Count
- PTHL 0
- IKNA 2
- Target Price
- PTHL N/A
- IKNA $3.00
- AVG Volume (30 Days)
- PTHL 295.9K
- IKNA 36.8K
- Earning Date
- PTHL 11-11-2024
- IKNA 11-07-2024
- Dividend Yield
- PTHL N/A
- IKNA N/A
- EPS Growth
- PTHL N/A
- IKNA N/A
- EPS
- PTHL N/A
- IKNA N/A
- Revenue
- PTHL $572,291.00
- IKNA $1,844,000.00
- Revenue This Year
- PTHL N/A
- IKNA N/A
- Revenue Next Year
- PTHL N/A
- IKNA N/A
- P/E Ratio
- PTHL N/A
- IKNA N/A
- Revenue Growth
- PTHL 2.32
- IKNA N/A
- 52 Week Low
- PTHL $3.32
- IKNA $1.02
- 52 Week High
- PTHL $6.45
- IKNA $4.63
- Technical
- Relative Strength Index (RSI)
- PTHL N/A
- IKNA 51.43
- Support Level
- PTHL N/A
- IKNA $1.67
- Resistance Level
- PTHL N/A
- IKNA $1.77
- Average True Range (ATR)
- PTHL 0.00
- IKNA 0.05
- MACD
- PTHL 0.00
- IKNA 0.00
- Stochastic Oscillator
- PTHL 0.00
- IKNA 45.45
About PTHL Pheton Holdings Ltd Class A Ordinary Shares
Pheton Holdings Ltd is a healthcare solutions provider dedicated to developing and commercializing treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a type of radiation therapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Its proprietary treatment planning system, FTTPS, is designed to promote the efficiency, accuracy, and safety of brachytherapy. FTTPS is a user-oriented treatment planning system, or TPS, for treating a wide variety of malignant tumors, which can determine the target volume, prescription dose, and dose limitation to protect OARs and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.